Somatic Advantage 74 (DNA+RNA)

Test Code
SLS162004
Book Now

What is Somatic Advantage 74 (SA74)?

The SA74 test evaluates mutations that may drive cancer development and progression in 74 genes using DNA sequencing and fusions in 14 genes using RNA sequencing. This broad-spectrum molecular test provides a detailed tumor profile, helping oncologists make informed decisions on targeted therapies, immunotherapies, and clinical trial eligibility.

Genes Covered/ No. of Genes: 74 Genes, 14 Fusions

Who Is This Test For?

Patients with solid tumors who require broad molecular profiling, or Individuals with advanced or treatment-resistant cancers, who are being considered for personalized treatment strategies or clinical trials

Key Features

  • Actionable Insights: Covers targetable genomic alterations in 74 clinically relevant genes associated with solid tumors, recommended by FDA and NCCN guidelines
  • Coverage: >1000x
  • Broad Genomic Spectrum: Covers SNVs/InDels, CNVs, and Fusions
  • Advanced Technology: State-of-the-art sequencing with Illumina® NovaSeq™ X Plus
  • Analytical Sensitivity: SNVs/InDels: 99% with 5% LOD, CNVs: 99.9% with >4.5 amplified genes, Fusions: 99.9% with >4 copies/ng of expressed fused genes
  • Assured Quality: Backed by Robust Validation and CAP/NABL Accreditations

Clinical Applications

  • Identifies actionable mutations for targeted therapy
  • Assesses resistance mechanisms to guide second-line or combination therapy options
  • Supports clinical trial eligibility and advanced treatment planning

All Solid Tumors, Comprehensive Profiling

Contact Us